Teva says oral Copaxone test completed


JERUSALEM , Feb 13 (Reuters) - Israel's Teva Pharmaceutical Industries Ltd. said the trial of the oral version of multiple sclerosis drug Copaxone has been completed.

Interim results showed the treatment had a positive effect -- although not at levels that were statistically significant, said a company spokeswoman for Teva, one of the world's largest generic drug companies.

In September, Teva said interim results of a trial of an oral version of Copaxone were disappointing. Teva had expected full results of the trial to be available by early 2002.

"We are currently studying the results of the experiment and weighing all alternatives along with our partner Lundbeck" of Denmark, the spokeswoman said.

Teva's Nasdaq-traded shares were down 85 cents at $59.75 in afternoon dealings.